Merck Signs US$922.5 M Collaboration with OPKO Health for Epstein-Barr Virus Vaccine

By Lalit Mishra & Lucy Haggerty

Pharma Deals Review: Vol 2023 Issue 3 (Table of Contents)

Published: 17 Mar-2023

DOI: 10.3833/pdr.v2023.i3.2771     ISSN: 1756-7874

Section: Research & Development



Jumping into the cancer vaccine arena, Merck has signed a global licensing agreement with Opko Health’s subsidiary, ModeX Therapeutics, for a vaccine candidate MDX-2201 targeting the Epstein-Barr virus (EBV) which could be worth up to US$922...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details